This week,
Medigus Ltd. (NASDAQ: MDGS, Forum) stock has climbed 0.68% and the company announced that
Polyrizon Ltd., submitted an additional patent application to the United States Patent and Trademark Office for its technology to prevent Pathogens such as COVID-19 and allergens from affecting nasal tissue.
Generally pertaining to the field of hydrogels that are capable to capture and contain biological assaults intrusion through the upper airways and eye cavities, the invention details a novel modality for a delivery system for drugs through the nasal mucosa that could get more drug into the body and resides longer in the nasal cavity.
For the full news update, click
here.
Medigus owns 35.86% of the private health care seed-stage company’s share capital and its
recent pre-clinical data showed that its product candidate has the potential to reduce the risk of an infection with human coronavirus and may also prevent COVID-19 as well as Influenza Virus H1N1 and could also potentially treat other cold viruses.
Polyrizon’s new product candidate protects the nasal cavity and the respiratory tract. In its H1N1 studies, product candidates demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibit cells death.
It was also pointed out that use of the Capture and Contain platform technology would help provide a boost in Polyrizon’s product line extended against flu and cold viruses along with a variety of different respiratory viruses.
Medigus is a technology company that works with advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions.
For more details on the company, visit
medigus.com.
FULL DISCLOSURE: Medigus Ltd. Is a client of Stockhouse Publishing.